Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Crushed vs Intact Cenobamate
NCT05572255Phase 1Completed
- Sponsor
- SK Life Science, Inc.
- Start
- Sep 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cenobamate in focal onset seizure (3 arms), sponsored by SK Life Science, Inc. Primary endpoints: Maximum Plasma Concentration up to 38 days, Area Under the Curve to the Last Quantifiable Concentration up to 38 days and 1 more. Started Sep 2022; status: completed.
02
Drugs
cenobamate
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT05572255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05572255.